汇丰研究发表报告指，京东健康(06618.HK) 2025年第一季毛利率和收入超出预期，因为专利药品强劲增长，以及非药品增长带来强劲广告收入。
京东健康持续投资于线下扩张，专注于增强线下基础设施和供应商关系。该行将京东健康2025至2027年收入预测上调4%至5%，净利润预测上调5%。考虑到2025年第一季强于预期的表现，该行将目标价从43元上调至45元，隐含约18%的上行空间。该股目前以2025年预计市盈率约21倍交易，对应2025至2026年每股盈利增长15%，估值合理；维持“持有”评级，认为业绩超预期已反映在股价中。(ad/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-13 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.